Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01253369 · ClinicalTrials.gov registry record · Phase 2
Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT01253369 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 33 participants.
The verdict
NCT01253369, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
Pazopanib is a drug that inhibits proteins thought to be important for new blood vessel formation. This drug has been used in other cancer research studies and information from those studies suggests that pazopanib may help block proteins that are important for the growth, invasion, and spread of cancer cells.
Interventions
- DRUG Pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2010-06 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01253369
The ClinicalTrials.gov registry entry for NCT01253369 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pazopanib is the first listed.
NCT01253369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01253369 about?
NCT01253369 is a clinical study titled "Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer". Pazopanib is a drug that inhibits proteins thought to be important for new blood vessel formation. This drug has been used in other cancer research studies and information from those studies suggests that pazopanib may help block proteins that are important for the growth, invasion, and spread of ca...
What is the current status of trial NCT01253369?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2010-06. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01253369?
The interventions under investigation include: Pazopanib (DRUG).
Who is sponsoring clinical trial NCT01253369?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.